Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals has reported Non-Current Assets for 6 years, with the latest figure at $8.2 million in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 6.72% year-over-year to $8.2 million in Q2 2026; TTM through Jun 2026 was $35.1 million, a 68.18% increase from a year earlier, with the FY2025 full-year figure at $9.0 million, up 113.56% from the prior year.
• Non-Current Assets was $8.2 million for Q2 2026 at Amylyx Pharmaceuticals, down from $8.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $52.8 million in Q4 2023, with the low at $3.5 million in Q1 2025.
• Average Non-Current Assets over 5 years is $13.1 million, with a median of $9.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 1305.73% in 2022, then plunged 92.04% in 2024.
• Over 5 years, Non-Current Assets stood at $9.3 million in 2022, then surged by 466.39% to $52.8 million in 2023, then slumped by 92.04% to $4.2 million in 2024, then surged by 113.56% to $9.0 million in 2025, then retreated by 8.34% to $8.2 million in 2026.
• The last three Non-Current Assets figures came in at $8.2 million (Q2 2026), $8.6 million (Q1 2026), and $9.0 million (Q4 2025), per Business Quant data.